Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 1
2006 2
2007 2
2008 3
2009 3
2010 1
2011 3
2012 2
2013 2
2014 1
2015 1
2017 2
2018 1
2019 2
2020 2
2021 1
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Machine learning for prediction of immunotherapeutic outcome in non-small-cell lung cancer based on circulating cytokine signatures.
Wei F, Azuma K, Nakahara Y, Saito H, Matsuo N, Tagami T, Kouro T, Igarashi Y, Tokito T, Kato T, Kondo T, Murakami S, Usui R, Himuro H, Horaguchi S, Tsuji K, Murotani K, Ban T, Tamura T, Miyagi Y, Sasada T. Wei F, et al. Among authors: igarashi y. J Immunother Cancer. 2023 Jul;11(7):e006788. doi: 10.1136/jitc-2023-006788. J Immunother Cancer. 2023. PMID: 37433717 Free PMC article.
Prospects for a personalized peptide vaccine against lung cancer.
Nakahara Y, Kouro T, Igarashi Y, Kawahara M, Sasada T. Nakahara Y, et al. Among authors: igarashi y. Expert Rev Vaccines. 2019 Jul;18(7):703-709. doi: 10.1080/14760584.2019.1635461. Epub 2019 Jun 28. Expert Rev Vaccines. 2019. PMID: 31225971 Review.
Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
Himuro H, Nakahara Y, Igarashi Y, Kouro T, Higashijima N, Matsuo N, Murakami S, Wei F, Horaguchi S, Tsuji K, Mano Y, Saito H, Azuma K, Sasada T. Himuro H, et al. Among authors: igarashi y. Cancer Immunol Immunother. 2023 Aug;72(8):2829-2840. doi: 10.1007/s00262-023-03464-w. Epub 2023 May 16. Cancer Immunol Immunother. 2023. PMID: 37188764 Free PMC article.
Depth inversion with a 3D structure influences brightness perception.
Arai T, Masuda T, Igarashi Y, Omori K, Aizawa Y, Masuda N. Arai T, et al. Among authors: igarashi y. PLoS One. 2019 Oct 18;14(10):e0224192. doi: 10.1371/journal.pone.0224192. eCollection 2019. PLoS One. 2019. PMID: 31626683 Free PMC article.
The tactile continuity illusion.
Kitagawa N, Igarashi Y, Kashino M. Kitagawa N, et al. Among authors: igarashi y. J Exp Psychol Hum Percept Perform. 2009 Dec;35(6):1784-90. doi: 10.1037/a0016891. J Exp Psychol Hum Percept Perform. 2009. PMID: 19968435
Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibody.
Nakahara Y, Matsutani T, Igarashi Y, Matsuo N, Himuro H, Saito H, Yamada K, Murotani K, Hoshino T, Azuma K, Sasada T. Nakahara Y, et al. Among authors: igarashi y. Cancer Immunol Immunother. 2021 Oct;70(10):2881-2892. doi: 10.1007/s00262-021-02900-z. Epub 2021 Mar 9. Cancer Immunol Immunother. 2021. PMID: 33751180 Free PMC article.
32 results